论文部分内容阅读
目的:观察拉米夫定联合胸腺肽α_1治疗慢性乙型肝炎的疗效。方法:80例慢性乙型肝炎患者随机分为两组.治疗组41例,应用胸腺肽α_1 1.6 mg,每周2次,ih,持续9个月,同时口服拉米夫定100 mg.qd,疗程12～13个月,平均12.2个月;对照组:39例,单用拉米夫定,用量及用法与治疗组相同,疗程12.5～13个月,平均12.8个月。观察两组治疗前、后症状、肝功能及病毒学指标。结果:治疗组在改善患者症状、恢复肝功能、HBeAg血清转换方面明显优于对照组,在HBV-DNA阴转方面无统计学差异。结论:拉米夫定、胸腺肽α_1两药联合治疗慢性乙型肝炎,具有明显的协同作用,较好的改善患者症状及恢复肝功能,更好的起到抗乙肝病毒作用。
Objective: To observe the efficacy of lamivudine combined with thymosin α_1 in the treatment of chronic hepatitis B patients. Methods: Eighty patients with chronic hepatitis B were randomly divided into two groups: 41 cases in the treatment group, thymosin α_1 1.6 mg twice a week for ih for 9 months, while oral lamivudine 100 mg.qd, 12 to 13 months, an average of 12.2 months; control group: 39 cases, lamivudine alone, the same amount and usage and treatment group, treatment of 12.5 to 13 months, an average of 12.8 months. The symptoms, liver function and virological indexes of the two groups before and after treatment were observed. Results: The treatment group was significantly better than the control group in improving symptoms and liver function, and HBeAg seroconversion. There was no significant difference in HBV-DNA overcast. Conclusion: The combination of lamivudine and thymosin α_1 in treating chronic hepatitis B has obvious synergetic effect, which can improve the symptoms of patients and restore the liver function, and play a better role in anti-hepatitis B virus.